Video

Emerging Agents for R/R CLL

Author(s):

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Related Videos
John M. Burke, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
David C. Fisher, MD
David C. Fisher, MD
Nitin Jain, MD
Related Content
Supriya Gupta, MD
January 9th 2025

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
January 8th 2025

Fixed-Duration Zanubrutinib/Venetoclax Shows Efficacy in R/R Chronic Lymphocytic Leukemia

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8